Sign in
Not yet taking people in United StatesPhase 1

Simultaneous Engagement of Networks for Alleviating Pain (SENAP)

Key facts

Who runs it
University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
20 people, planned
Starts
1 Jan 2027
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • PFM-guided cortical stimulation
Record updated
3 November 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Age ≥ 22 years
  • Clinical diagnosis of a refractory chronic neuropathic pain syndrome suggestive of deafferentation or central pain. Non-limiting examples of these syndromes are:
  • post-traumatic pain syndromes (e.g. plexopathies, radiation-induced injury)
  • postsurgical pain syndromes (e.g. phantom limb pain, anesthesia dolorosa)
  • postherpetic neuralgia
  • Central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)
  • Greater than 6 months of chronic neuropathic pain
  • Average pain intensity over the past 30 days reported as 6 or greater on a 0-10 numeric rating scale (NRS)
  • Multidisciplinary pain consensus review that establishes
  • Pain is refractory to medical management
  • Pain that is refractory to or unlikely to be altered by less invasive treatment and
  • Pain distribution either does not permit attempts at relief by a targeted nerve block (e.g., post-stroke pain) or such blocks have provided <25% relief
  • Medication doses currently stable (no active titration or drug trials in progress) in the 30 days prior to baseline (immediately pre-surgical) study visit
  • Ability to speak / read English
  • Capable of understanding and providing informed consent (verified if necessary by a standard tool such as the MacArthur Competency Assessment)
  • Women of childbearing age must be on regular use of an accepted contraceptive method(s)

Who cannot take part

  • Pregnancy, breastfeeding, or unwilling to maintain regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study if study procedures may cause risk to the fetus. Patients who become pregnant prior to the surgical implantation will be excluded from the study
  • Inability to temporarily stop anticoagulation therapy (approximately 3 weeks total) for surgery and after surgery. Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation
  • Previous ablative intracranial surgery for the management of a central pain syndrome
  • Any other condition that, in the judgment of the PI or the Data Safety \& Monitoring Board, significantly increases risk of receiving an implanted neurostimulator
  • Untreated or uncontrolled psychiatric illness (schizophrenia, bipolar disorder, obsessive-compulsive disorder), or personality disorders (e.g. borderline personality disorder) or other neuropsychiatric conditions that the evaluating clinician would recommend exclusion of the patient after neuropsychiatric evaluation
  • History of seizure disorder and seizure within the last year. Participants with a remote history of epilepsy will need documentation from their neurologist for eligibility
  • MRI (done within one year of the baseline period) with significant abnormalities other than those associated with the neurological disorder causing chronic pain
  • history of other neurosurgical procedures that may interfere with functioning of the device
  • Requires ongoing or expected diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition
  • Allergies or known hypersensitivity to materials in the implanted system (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel)
  • Those who require ongoing monitoring of a disease state by MRI
  • History of diagnosed substance use disorder in the past 3 years. Benzodiazepines and/or opioids prescribed by a physician with use as directed do not count for this criterion. Cannabis/cannabinoid products will not be considered an exclusion if used under the auspices of a state-sponsored medical cannabis program
  • Major medical comorbidities increasing the risk of surgery including uncontrolled hypertension, severe diabetes, major organ system failure, need for chronic anticoagulation other than aspirin, active infection, immunocompromised state, or malignancy with < 5 years life expectancy
  • Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI
  • Suicide attempt within 12 months from baseline visit or imminent suicide risk in the judgment of study clinicians
  • Modified Scale for Suicidal Ideation Score of greater than or equal to 21
  • Implantable hardware not compatible with MRI or with the study or former metal worker that may pose risk from MRI
  • Active, pending, or planned litigation or workman's compensation claim related to the pain/injury. Current receipt of disability benefits, without a dispute or litigation, is not an exclusion
  • Inability to target the somatocognitive action network or cingulate opercular network on fMRI

Where in United States

  • University of MinnesotaMinneapolis, United StatesContact: Matthew MapleNot yet recruiting

About the trial

What the trial wants to find out

This trial is investigating the acceptability and efficacy of PFM-guided cortical stimulation for the treatment of central neuropathic pain.

The group in the trial

  • PFM-guided cortical stimulationTreatment being tested

    Abbott Eterna IPG and Lamitrode 44 paddles with accessory extensions and clinical programmers

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 November 2026